News & events
Press Releases
On the 28th March 2022, OncoArendi changed its name to Molecure
Molecure Receives Positive IDMC Recommendation to Continue the KITE Clinical Trial Without Changes to the Study Protocol (OATD-01 Development Program)
24 July 2026
Molecure focuses on the most commercially promising projects and closes the RNA program
30 January 2026
Molecure at the threshold of a breakthrough in the treatment of inflammatory and fibrotic diseases. The focus on the most breakthrough therapy and the OATD-01 and OATD-02 clinical trials results in a reduction of programs in the discovery phase from five to three
15 October 2024
Molecure (WSE: MOC) and Nasdaq-listed biotechnology company Ocean Biomedical (NASDAQ: OCEA) sign an exclusive licensing agreement for the development and commercialization of selective YKL-40 inhibitors
15 October 2024
Invitation to investor meeting 16th October 2024, 10:00 am (CET)
14 October 2024
Events & Presentations
Fibrosis and Tissue Repair: From Molecules and Mechanics to Therapeutic Approaches – February 19-23, 2020 | Victoria, BC, Canada
27 February 2020
ACS National Meeting & Expo – August 25 – 29, 2019 | San Diego, CA
4 September 2019
EFMC – YMCS – Young Medicinal Chemist Symposium – Ljubljana 02-06.09.2018
17 September 2018